PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|July 1, 2011
Vetter dual-chamber technology
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject® syringe and dual-chamber V-LK® cartridge.
Advertisement
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject ® syringe and dual-chamber V-LK ® cartridge. Lyophilized drug resides in one chamber; diluent in the other. The drug is reconstituted just prior to administration in a few simple steps.
Competitive advantages
- Product differentiation in a competitive arena, whether at initial launch or as part of a product lifecycle management strategy
- Market opportunity in a growing homecare sector, as patients and caregivers seek drug-delivery systems easy and safe enough to use independently
- Increased API yield, due to reduced overfill requirements
Dosage forms:
In addition to lyophilized-drug/diluent combinations, dual-chamber systems may also be used for liquid/liquid or powder/liquid drug combinations that require separation until point of use.
Sizes:
Dual-chamber syringe: in 1 ml, 2.5 ml and 5 ml sizes, covering fill volumes of 0.1 ml - 5 ml per chamber
Dual-chamber cartridge: in 1.5 ml size, covering fill volumes of 0.1 ml - 1.4 ml (first chamber) and 0.1 ml - 1.3 ml (second chamber)
For US inquiries please contact
+1-847-581-6888 or
For EU inquiries please contact
+49-751-3700-0 or
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement